MRUS

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-67.9M ExitQ4 2025 $68M -- $90.00
Steven CohenPoint72 $-24.0M ExitQ4 2025 $24M -- $90.00
Ron BaronBaron Capital $-470.8K ExitQ4 2025 $471k -- $90.00
George SorosSoros Fund Management $-38.1M ExitQ4 2025 $38M -- $90.00
Polen CapitalInvestor $-1.1M ExitQ4 2025 $1M -- $90.00

Insider Trades

Name	Value	Action	Price	Current Price
Genmab A/s10 Percent Owner $7B75.9M shares BuyDec 29, 2025 $97.00 $90.00
Genmab A/s10 Percent Owner $102M1.1M shares BuyDec 29, 2025 $97.00 $90.00
Genmab A/s10 Percent Owner $289k3k shares BuyDec 26, 2025 $97.00 $90.00
Genmab A/s10 Percent Owner $14M142.6k shares BuyDec 26, 2025 $97.00 $90.00
Genmab A/s10 Percent Owner $9M96.1k shares BuyDec 24, 2025 $97.00 $90.00
Genmab A/s10 Percent Owner $54M561k shares BuyDec 23, 2025 $97.00 $90.00

News

globenewswire.comLeonaBio Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 7

Trade MRUS

About Merus N.V.

Merus N.V. is a clinical-stage immuno-oncology firm based in the Netherlands, specializing in the discovery and advancement of bispecific antibody therapies. Established in 2003, the company maintains its headquarters in Utrecht. Its robust pipeline of bispecific antibody candidates includes Zenocutuzumab (MCLA-128), which is currently undergoing Phase 2 clinical trials for the treatment of patients with metastatic breast cancer, and is also in Phase 1/2 clinical trials for solid tumors that exhibit Neuregulin 1 expression. Merus is also actively developing several other compounds: MCLA-158: In Phase 1 clinical trials for solid tumors. MCLA-145: Also in Phase 1 clinical trials for various solid tumors. MCLA-129: Progressing through Phase 1/2 clinical trials for advanced non-small cell lung cancer (NSCLC) and other solid tumors. ONO-4685: Currently in Phase 1 clinical trials to address relapsed/refractory T-cell lymphoma. Furthermore, Merus engages in strategic partnerships. It collaborates with Betta Pharmaceuticals Co. Ltd on the research and development of specific bispecific antibody candidates, including MCLA-129. Additionally, Incyte Corporation is partnering with Merus for the development of MCLA-145.

CEO: Jan van de Winkel
IPO Date: May 19, 2016

Market Data

Open: $90.00
High: $90.00
Low: $90.00
Volume: 2.7M
52W High: $97.14
52W Low: $33.19

Valuation

Market Cap: $6.8B
Enterprise Value: $6.5B

Financials

Free Cash Flow: -$187.5M
Revenue: $34.9M
Net Income: -$207.9M
Cash: $293.3M
Debt: $9.9M

Events

EarningsOct 31

EPS est. -1.23 · actual -1.23